FALLS CHURCH, Va.–(BUSINESS WIRE)–Retension Pharmaceuticals, Inc. is pleased to announce the successful closing of its Series A $10.4 million financing round to initiate a well-powered and controlled Phase 2 clinical study in patients with hypertension uncontrolled on two or more antihypertensives. Inhibition of PDE5 is a long-desired mechanism for enhancing NO-based […]
Other News
B-Secur and FIRMINIQ Join Forces to Transform Cardiovascular Health Management
PLANO, Texas & BELFAST, Northern Ireland–(BUSINESS WIRE)–B-Secur, a leader in advanced biosensing technology, and FIRMINIQ, a software product development company specializing in connected health, are proud to announce a strategic partnership aimed at transforming cardiovascular health management globally. “Our new alliance with FIRMINIQ represents a significant leap forward in how we […]
Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress
Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company’s ongoing proof-of-concept (PoC) human clinical trial
Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery Calcium
HealthCCSng V2.0 introduces additional ‘zero calcium’ categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
Gosselies (Belgium), August 21, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies to prevent and treat thrombotic and inflammatory diseases, announces today that the DMC reviewed the data from the first 8 patients in a planned review of the ongoing BIRCH Phase 2a trial of BIOX-101 to prevent secondary damage after intracerebral hemorrhagic stroke (ICH).
Adagio Medical Provides Business Updates
August 19, 2024 04:01 PM Eastern Daylight Time LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. “For years there has been underinvestment in and pent-up demand for innovation in ablation […]
Johnson & Johnson to Acquire V-Wave
V-Wave’s Novel and Minimally Invasive Interatrial Shunt is Designed to Treat Heart Failure and Addresses Significant Treatment Gap Device Further Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular August 20, 2024 07:30 AM Eastern Daylight Time NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson1 (NYSE: JNJ) today announced that it has entered into […]
AVS Partners with the Jacobs Institute to Expedite Clinical Trials for Coronary and Carotid Indications
August 20, 2024 07:58 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its Pulse Intravascular Lithotripsy platform, today announced it has entered into a strategic agreement with the Jacobs Institute, a nonprofit medical device […]
MemorialCare’s Long Beach Medical Center and Saddleback Medical Center Nationally Recognized by the American Heart Association with Get with the Guidelines Gold Plus Awards
FOUNTAIN VALLEY, Calif., Aug. 20, 2024 /PRNewswire/ — MemorialCare’s Long Beach Medical Center and Saddleback Medical Center received the American Heart Association’s Get With The Guidelines® – Stroke Gold Plus quality achievement awards. Long Beach Medical Center also received the Get…
Recent
Efemoral Medical Reports Exceptional Long-Term EFEMORAL I Results Highlighting Durability and Differentiated Performance in Femoropopliteal Disease
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
First Peer-Reviewed Study to Evaluate AI-Generated Impressions Demonstrates Radiologist Preference for Domain-Specific Versus General Models
Popular
- No commented posts yet